Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Knowing when to adjust is key. This piece outlines clear signals that your Zero Based Budget needs updating and the next steps to take.
19,541 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
As winter approaches, Vail Resorts relies on Epic Pass momentum to power revenue and cash flow. This investor-focused...
As AI and automation reshape the job landscape, building passive income becomes a priority. Here are three high-yield...
Rigetti Computing has dropped about 70% from its 52-week high. This article breaks down whether the dip offers real u...
A shift in how firms anchor themselves abroad is gaining momentum as U.S. and Chinese authorities scrutinize origin a...
A biotech stock nearly 300% pop grabbed the attention of major investors, culminating in a $68.7 million stake as a b...
Palantir connects data, software, and decision-making in a way that could reshape enterprise AI. This guide outlines ...
Vice Capital Markets launches a public daily Par Note Rate benchmark, providing a market-based view of mortgage prici...
Veteran investor Mark Kvamme is rolling out a Temasek style OHIO Fund, a $500 million vehicle aimed at accelerating g...
Qualcomm sits at the intersection of phones, cars, and AI tech. This guide breaks down what qualcomm stock investors ...
Hesai's early 2026 earnings signal a turning point for LiDAR tech adoption. This guide breaks down the Q1 results, wh...
In 2026, the iMGP DBi Managed Futures Strategy ETF (DBMF) is delivering an 11% year-to-date gain against a roughly 5%...